Description: <b>Formononetin</b> is an O-methylated isoflavone.<br>
-Ononin is formononetin-7-O-β-D-glucoside, meaning formononetin with a glucose attached at the 7-position.<br>
Found in several plant sources, including:<br>
<br>
Red Clover (Trifolium pratense):<br>
Astragalus membranaceus:<br>
Other Leguminous Plants:<br>
-Various plants in the legume family (Fabaceae) may also contain formononetin, although the levels and bioavailability can differ depending on the plant species and extraction methods.<br>
<br>
Pathways:<br>
PI3K/Akt Pathway: formononetin may inhibit the phosphorylation of Akt<br>
(MAPK) Pathway: may modulate components of the MAPK pathway<br>
STAT3 Signaling Pathway: formononetin can downregulate STAT3 activity<br>
NF-κB Pathway: modulating NF-κB activation<br>
Apoptotic Pathways: via mitochondrial-dependent pathways, enhancing caspase activation <br>
Induce cell cycle arrest at different checkpoints (e.g., G1 or G2/M phases)<br>
<br>
Formononetin, a naturally occurring isoflavone found in red clover, Astragalus membranaceus, and other leguminous plants, shows promise as an anticancer agent. Its ability to modulate key signaling pathways—including PI3K/Akt, MAPK, STAT3, NF-κB, and apoptotic and cell cycle regulatory mechanisms—suggests a multifaceted potential in cancer prevention and therapy.<br>
<br>
<p><b>Formononetin</b> — Formononetin is a naturally occurring O-methylated isoflavone and phytoestrogen found primarily in red clover, Astragalus membranaceus, licorice, kudzu, and other Fabaceae plants. It is classified as a plant-derived isoflavonoid small molecule and is commonly abbreviated FMN, FNT, FT, or Form. Formononetin is also produced from its glycoside ononin and is extensively converted in vivo to daidzein and phase-II conjugates. Its anticancer activity remains experimental and is complicated by concentration-dependent estrogen-receptor signaling, limited aqueous solubility, rapid metabolism, and comparatively low systemic exposure to unconjugated parent compound.</p>
<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li>Suppression of receptor tyrosine kinase and survival signaling, particularly IGF1R, EGFR, PI3K, AKT, and mTOR pathways.</li>
<li>Induction of mitochondrial apoptosis through ↑ Bax/Bcl-2 ratio, caspase activation, PARP cleavage, and suppression of MCL-1 and other survival proteins.</li>
<li>Inhibition of JAK1/JAK2–STAT3/STAT5 signaling, including reduced STAT nuclear translocation, transcriptional activity, and downstream proliferative and anti-apoptotic proteins.</li>
<li>Cell-cycle arrest through ↓ cyclin D1 and related cell-cycle regulators, commonly producing G0/G1 arrest, although the phase is model-dependent.</li>
<li>Context-dependent oxidative stress induction, with ↑ ROS and glutathione imbalance contributing to STAT inhibition, apoptosis, ferroptotic signaling, and reversal of multidrug resistance.</li>
<li>Suppression of invasion and metastasis through modulation of MMP2/9, EMT-related signaling, EphB3, ERK, NF-κB, AP-1, and regulatory non-coding RNAs.</li>
<li>Immune-checkpoint modulation through ↓ MYC–STAT3-dependent PD-L1 synthesis and increased lysosomal PD-L1 degradation.</li>
<li>Chemosensitization through inhibition of drug-efflux transporters, autophagy or mitophagy modulation, and suppression of survival pathways.</li>
<li>Estrogen-receptor modulation, including ERα agonism and ERβ-associated effects; biological direction is concentration-, tissue-, and receptor-context-dependent.</li>
</ol>
<p><b>Bioavailability / PK relevance:</b> Native formononetin has poor water solubility, substantial intestinal and hepatic first-pass metabolism, rapid glucuronidation and sulfation, and extensive O-demethylation to daidzein. Rat oral bioavailability has been reported at approximately 22%, but this does not establish comparable human exposure. Free parent formononetin generally represents only a small fraction of circulating total isoflavones. Phospholipid, nanoparticle, lipid, and bioenhancer formulations can increase exposure in animals but are not validated cancer treatments.</p>
<p><b>In-vitro vs systemic exposure relevance:</b> Many anticancer studies use approximately 20–100 µM formononetin, whereas exposure to unconjugated parent compound after ordinary oral red-clover or dietary-isoflavone intake is generally much lower. Consequently, many direct cytotoxic, ROS-generating, STAT-inhibitory, and apoptosis-inducing findings occur at concentrations unlikely to be achieved systemically with conventional oral preparations. Lower concentrations may instead produce estrogenic or proliferative effects in ERα-positive cells, creating a clinically important biphasic-response concern.</p>
<p><b>Clinical evidence status:</b> Preclinical. Evidence includes cancer-cell experiments and multiple murine xenograft or carcinogenesis models. No established formononetin monotherapy or adjunctive cancer regimen is supported by completed randomized clinical trials, and formononetin is not an approved anticancer drug. Human trials involving red-clover isoflavone mixtures address menopausal, vascular, or bone outcomes rather than cancer treatment and cannot be attributed specifically to formononetin.</p>
<p><b>Safety considerations:</b> Human safety data for purified formononetin are limited. Its ERα agonist and phytoestrogen properties warrant caution in estrogen-sensitive malignancies and in patients using endocrine therapies. Experimental studies demonstrate concentration-dependent stimulation of ERα-positive breast-cancer cells at low micromolar concentrations and inhibition at higher concentrations. Potential interactions may also arise through drug-efflux transporters, CYP enzymes, glucuronidation pathways, anticoagulant drugs, or combination chemotherapy. Long-term reproductive, endocrine, hepatic, and oncologic safety of pharmacological-dose purified formononetin remains unresolved.</p>
<br><br>
<h3>Formononetin Mechanistic Profile</h3>
<table>
<thead>
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Cancer Cells</th>
<th>Normal Cells</th>
<th>TSF</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>IGF1R EGFR PI3K AKT mTOR</td>
<td>IGF1R↓ EGFR↓ PI3K↓ AKT↓ mTOR↓</td>
<td>Context-dependent</td>
<td>R G</td>
<td>Reduced survival and proliferation</td>
<td>One of the most consistently reported anticancer axes; upstream receptor affected varies by cancer model.</td>
</tr>
<tr>
<td>2</td>
<td>Mitochondrial apoptosis</td>
<td>Bax↑ Bcl-2↓ MCL-1↓ caspase-3/9↑ PARP cleavage↑</td>
<td>Usually protective or mixed (context-dependent)</td>
<td>G</td>
<td>Apoptotic cell death</td>
<td>Observed in breast, cervical, ovarian, prostate, lung, osteosarcoma, gastric, colorectal, and myeloma models.</td>
</tr>
<tr>
<td>3</td>
<td>JAK STAT signaling</td>
<td>JAK1↓ JAK2↓ STAT3↓ STAT5↓</td>
<td>JAK STAT↓ during inflammatory stress</td>
<td>R G</td>
<td>Reduced transcription of survival and inflammatory genes</td>
<td>Includes reduced STAT phosphorylation, DNA binding, and nuclear translocation.</td>
</tr>
<tr>
<td>4</td>
<td>Cell-cycle regulation</td>
<td>Cyclin D1↓ CDK activity↓ G0/G1 arrest↑</td>
<td>Mixed</td>
<td>G</td>
<td>Proliferation arrest</td>
<td>Checkpoint is model-dependent; G0/G1 arrest is best characterized in breast and colorectal models.</td>
</tr>
<tr>
<td>5</td>
<td>Oxidative stress and glutathione</td>
<td>ROS↑ GSH/GSSG ratio↓</td>
<td>ROS↓ or antioxidant defenses↑ (context-dependent)</td>
<td>P R</td>
<td>Redox-mediated apoptosis and signal inhibition</td>
<td>Pro-oxidant activity is prominent in myeloma and multidrug-resistant cancer models but is dose-dependent.</td>
</tr>
<tr>
<td>6</td>
<td>Ferroptosis and lipid redox metabolism</td>
<td>Lipid peroxidation↑ GPX4-related defense↓ ferroptosis↑</td>
<td>Ferroptosis↓ in some tissue-injury models</td>
<td>R G</td>
<td>Iron-dependent oxidative cell death</td>
<td>Emerging mechanism with opposite effects possible in cancer versus normal-tissue injury models.</td>
</tr>
<tr>
<td>7</td>
<td>Ras MAPK ERK p38</td>
<td>ERK1/2↓ or p38↑</td>
<td>Context-dependent</td>
<td>R G</td>
<td>Apoptosis and growth suppression</td>
<td>Direction differs by MAPK branch and cancer type; p38 activation can be pro-apoptotic while ERK suppression reduces survival.</td>
</tr>
<tr>
<td>8</td>
<td>NF-κB and AP-1</td>
<td>NF-κB↓ AP-1↓</td>
<td>NF-κB↓ during inflammatory activation</td>
<td>R G</td>
<td>Reduced inflammation, survival, and invasion</td>
<td>Particularly documented in myeloma and neuroinflammatory or vascular stress models.</td>
</tr>
<tr>
<td>9</td>
<td>PD-L1 immune checkpoint</td>
<td>MYC↓ STAT3↓ PD-L1↓ lysosomal degradation↑</td>
<td>Not established</td>
<td>G</td>
<td>Enhanced cytotoxic T-cell activity</td>
<td>Demonstrated in cervical-cancer co-culture and xenograft systems; clinical immunotherapy relevance is unproven.</td>
</tr>
<tr>
<td>10</td>
<td>Invasion EMT and matrix remodeling</td>
<td>MMP2↓ MMP9↓ migration↓ invasion↓ EMT↓</td>
<td>Endothelial migration↑ in some models</td>
<td>G</td>
<td>Reduced metastatic phenotype</td>
<td>Cancer-cell inhibition conflicts with pro-migratory and pro-angiogenic ERα effects reported in normal endothelial cells.</td>
</tr>
<tr>
<td>11</td>
<td>Estrogen receptor signaling</td>
<td>ERα agonism↑ or ERβ-associated suppression↑ (dose-dependent)</td>
<td>ERα↑ ERβ↑ (tissue-dependent)</td>
<td>R G</td>
<td>Biphasic estrogenic modulation</td>
<td>Low micromolar exposure may stimulate ERα-positive breast-cancer proliferation, whereas higher concentrations may inhibit proliferation and induce apoptosis.</td>
</tr>
<tr>
<td>12</td>
<td>Angiogenesis</td>
<td>Angiogenesis↓ secondary to STAT3 PD-L1 or tumor suppression</td>
<td>ERα ROCK-II MMP2/9↑ angiogenesis↑</td>
<td>G</td>
<td>Strongly context-dependent vascular effect</td>
<td>Formononetin can promote endothelial migration and vascular sprouting; it should not be categorized as a uniformly anti-angiogenic compound.</td>
</tr>
<tr>
<td>13</td>
<td>Autophagy and mitophagy</td>
<td>Autophagy↓ or mitophagy altered (model-dependent)</td>
<td>Frequently protective autophagy↑</td>
<td>G</td>
<td>Chemosensitization or stress adaptation</td>
<td>Taxane-resistant and triple-negative breast-cancer studies report reversal of resistance through autophagy or BACH1-associated mitophagy regulation.</td>
</tr>
<tr>
<td>14</td>
<td>Drug efflux and multidrug resistance</td>
<td>P-glycoprotein↓ ABCC2↓ intracellular chemotherapy↑</td>
<td>Drug-disposition effects possible</td>
<td>R G</td>
<td>Chemosensitization</td>
<td>Synergy has been reported with bortezomib, paclitaxel, vincristine, doxorubicin, and 5-fluorouracil in preclinical systems.</td>
</tr>
<tr>
<td>15</td>
<td>Clinical Translation Constraint</td>
<td>High experimental concentrations; heterogeneous and biphasic responses</td>
<td>Estrogenic and pro-angiogenic activity possible</td>
<td>G</td>
<td>Limits direct clinical extrapolation</td>
<td>Poor solubility, extensive metabolism, low free-parent exposure, formulation dependence, absent cancer trials, and unresolved safety in hormone-sensitive disease.</td>
</tr>
</tbody>
</table>
<p>P: 0–30 min R: 30 min–3 hr G: >3 hr</p>